Company reports Q2 revenue of $548 million and raises full-year earnings outlook amid improved profitability metrics.
ICU Medical raised its 2026 adjusted earnings per share outlook to a range of $8.60 to $9.00, citing stronger-than-expected gross margins of 41.5%. The company reported Q2 revenue of $548 million, reflecting 6% organic growth, alongside adjusted EBITDA of $110 million and adjusted EPS of $2.37.
The revised guidance follows a quarter where profitability metrics improved, including a 41% adjusted gross margin, up from prior periods. Management highlighted progress in deleveraging and operational efficiency as key drivers behind the upward revision.
Shares showed muted reaction in after-hours trading as investors digested the updated outlook and quarterly performance.